
|Articles|September 18, 2015
Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
There are many clinical trial opportunities, Tolaney says, before surgery.
Advertisement
Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.
“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
6 Cancer Drugs FDA Approved in August 2026 and What They Mean for You
2
What Breast Cancer Survivors Should Know About Weight Loss and Long-Term Health
3
Diagnosed With Ovarian Cancer at 15: 10 Things That Helped Brynn Forlizzi Through Treatment
4
Lung Cancer Patient Shares How Community, Hope and Self-Advocacy Helped Her Through Treatment
5




